NEW YORK (GenomeWeb News) — MorphoSys today said Genesis Research and Development will continue using HuCAL-based antibodies in its drug-development research.
New Zealand-based Genesis will use the antibodies, developed by MorphoSys’ AbD Serotec segment, against the target molecule FGFR5 for validations and pre-clinical studies for its Zyrogen drug, which is being studied for certain autoimmune diseases, according to Genesis’ website.
Depending on the results of the study using the antibodies, the companies will discuss continuing the development of the therapeutic program, MorphoSys said.
"The collaboration with Genesis provides us with access to an innovative and scientifically attractive target molecule which may lead to lucrative future commercial opportunities for MorphoSys," MorphoSys CEO Simon Moroney said in a statement.
Financial terms of the agreement were not released.